Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072046 | 0.76 | ALDH1A1 (0.51) | KMT2AALDH1A1MEN1ALOX12NPSR1 | |
| SCHEMBL7072042 | 0.76 | ALDH1A1 (0.51) | KMT2AALDH1A1MEN1ALOX12NPSR1 | |
| SCHEMBL7214820 | 0.74 | CPB1 (0.40) | KMT2AALDH1A1MEN1CYP2C9LMNA | |
| SCHEMBL7214815 | 0.74 | CPB1 (0.40) | KMT2AALDH1A1MEN1CYP2C9LMNA | |
| SCHEMBL23880053 | 0.70 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL7213941 | 0.69 | CA2 (0.43) | KMT2AALDH1A1MEN1HTTNPSR1 | |
| SCHEMBL7037202 | 0.69 | GSTP1 (0.39) | KMT2AALDH1A1MEN1L3MBTL1CYP2C9 | |
| SCHEMBL7090127 | 0.68 | GAA (0.39) | — | |
| SCHEMBL5408623 | 0.67 | CA2 (0.39) | KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL4370834 | 0.67 | CA2 (0.39) | KMT2AALDH1A1MEN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624158-B2 | Compound for use in the treatment of; sepsis, urogential, psychological, nervous system, respiratory, inflammatory, skin vascular and arthritic; wound healing agents | PFIZER INC | 2003-09-23 | — | — | US | disclosed |
| EP-1317465-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020072597-A1 | Purine derivatives | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| WO-2002022630-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072597-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | KMT2A 4442/4885ALDH1A1 226/4885MEN1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.